Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 207

1.

Paroxetine: current status in psychiatry.

Pae CU, Patkar AA.

Expert Rev Neurother. 2007 Feb;7(2):107-20. Review. Erratum in: Expert Rev Neurother. 2007 Mar;7(3):313-4.

PMID:
17286545
2.

Paroxetine: safety and tolerability issues.

Marks DM, Park MH, Ham BJ, Han C, Patkar AA, Masand PS, Pae CU.

Expert Opin Drug Saf. 2008 Nov;7(6):783-94. doi: 10.1517/14740330802423168 . Review.

PMID:
18983224
3.

[Efficacy and tolerability of escitalopram in anxiety disorders: a review].

Pelissolo A.

Encephale. 2008 Sep;34(4):400-8. doi: 10.1016/j.encep.2008.04.004. Epub 2008 Aug 15. Review. French.

PMID:
18922243
4.

Paroxetine: a review.

Bourin M, Chue P, Guillon Y.

CNS Drug Rev. 2001 Spring;7(1):25-47. Review.

5.

Use of paroxetine for the treatment of depression and anxiety disorders in the elderly: a review.

Bourin M.

Hum Psychopharmacol. 2003 Apr;18(3):185-90. Review.

PMID:
12672169
6.

Selective serotonin-reuptake inhibitors: an update.

Masand PS, Gupta S.

Harv Rev Psychiatry. 1999 Jul-Aug;7(2):69-84. Review.

PMID:
10471245
7.

Clinical experience with paroxetine in social anxiety disorder.

Baldwin DS.

Int Clin Psychopharmacol. 2000 Jul;15 Suppl 1:S19-24.

PMID:
10994679
8.

Obsessive-compulsive disorder: implications of the efficacy of an SSRI, paroxetine.

Ninan PT.

Psychopharmacol Bull. 2003 Spring;37 Suppl 1:89-96. Review.

PMID:
14566204
9.

Paroxetine.

Tang SW, Helmeste D.

Expert Opin Pharmacother. 2008 Apr;9(5):787-94. doi: 10.1517/14656566.9.5.787 . Review.

PMID:
18345955
10.

Remission rates in patients with anxiety disorders treated with paroxetine.

Ballenger JC.

J Clin Psychiatry. 2004 Dec;65(12):1696-707.

PMID:
15641876
11.

Paroxetine and its uses in psychiatry.

Bell C, Nutt D.

Hosp Med. 1999 May;60(5):353-6.

PMID:
10396411
12.

Selective serotonin reuptake inhibitors in the treatment of paediatric anxiety disorders: a review.

Murphy TK, Bengtson MA, Tan JY, Carbonell E, Levin GM.

Int Clin Psychopharmacol. 2000 Aug;15 Suppl 2:S47-63. Review.

PMID:
11110019
13.

Anxiety disorders: a review of tricyclic antidepressants and selective serotonin reuptake inhibitors.

Zohar J, Westenberg HG.

Acta Psychiatr Scand Suppl. 2000;403:39-49. Review.

PMID:
11019934
14.

Differences in total medical costs across the SSRIs for the treatment of depression and anxiety.

Sheehan DV, Eaddy MT, Shah MB, Mauch RP.

Am J Manag Care. 2005 Oct;11(12 Suppl):S354-61.

15.

The selective serotonin reuptake inhibitor paroxetine is effective in more generalized and in less generalized social anxiety disorder.

Stein DJ, Stein MB, Goodwin W, Kumar R, Hunter B.

Psychopharmacology (Berl). 2001 Nov;158(3):267-72.

PMID:
11713616
16.

Remission of generalized anxiety disorder: a review of the paroxetine clinical trials database.

Rickels K, Rynn M, Iyengar M, Duff D.

J Clin Psychiatry. 2006 Jan;67(1):41-7.

PMID:
16426087
17.

Potential indications for the selective serotonin reuptake inhibitors.

Boyer WF.

Int Clin Psychopharmacol. 1992 Jun;6 Suppl 5:5-12. Review.

PMID:
1431022
18.

Spotlight on paroxetine in psychiatric disorders in adults.

Wagstaff AJ, Cheer SM, Matheson AJ, Ormrod D, Goa KL.

CNS Drugs. 2002;16(6):425-34. Review.

PMID:
12027788
19.

Paroxetine response and tolerability among ethnic minority patients with mood or anxiety disorders: a pooled analysis.

Roy-Byrne PP, Perera P, Pitts CD, Christi JA.

J Clin Psychiatry. 2005 Oct;66(10):1228-33.

PMID:
16259535
20.

Efficacy and tolerability of controlled-release paroxetine.

Golden RN.

Psychopharmacol Bull. 2003 Spring;37 Suppl 1:176-86. Review.

PMID:
14566210

Supplemental Content

Support Center